Regeneron (REGN)

559.78 -13.83 (2.41%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/20 *Est.)

Latest Headlines

Regeneron Monoclonal Antibody Data Increases Probability Of COVID-19 Vaccine Success - Morgan Stanley September 30, 2020 8:46 AM - StreetInsider Regeneron (REGN) IV at 38 into providing initial data on its COVID-19 therapeutic antibody cocktail September 30, 2020 4:44 AM - StreetInsider Options expected to have increasing volume: CAG MKC PRGS BA PENN REGN September 30, 2020 4:30 AM - StreetInsider Regeneron (REGN) to Resume Trading at 5:35 p.m. September 29, 2020 5:02 PM - StreetInsider Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms September 29, 2020 4:12 PM - StreetInsider Regeneron (REGN) REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients September 29, 2020 4:02 PM - StreetInsider Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients September 29, 2020 4:01 PM - PR NewsWire Regeneron (REGN) Halted, News Pending September 29, 2020 4:00 PM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Sep 22 Filed by: BROWN MICHAEL S September 23, 2020 4:01 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Sep 21 Filed by: GOLDSTEIN JOSEPH L September 23, 2020 4:01 PM - SEC Filing Regeneron (REGN), Sanofi (SNY) Announce Late-breaking ESMO Presentation Shows Libtayo Monotherapy Increases OS in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% September 21, 2020 8:27 AM - StreetInsider Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% September 21, 2020 8:25 AM - PR NewsWire Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% September 21, 2020 8:25 AM - StreetInsider Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% September 20, 2020 8:25 PM - StreetInsider Regeneron (REGN) Positive Pivotal Data for Libtayo Monotherapy in Locally Advanced BCC Featured as Late-breaking Presentation at ESMO September 18, 2020 6:07 AM - StreetInsider Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO September 18, 2020 3:05 AM - PR NewsWire Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO  September 18, 2020 3:05 AM - StreetInsider Lilly says antibody drug cuts COVID-19 hospitalization, may seek emergency use nod September 16, 2020 7:07 AM - StreetInsider S&P 500 Buybacks Decline 55.4% in Q2, Trend Expected to Continue in Q3 September 15, 2020 11:20 AM - StreetInsider S&P 500 Buybacks Decline 55.4% to $88.7 Billion; Significant Reductions Expected to continue in Q3 2020 September 15, 2020 10:15 AM - PR NewsWire Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium September 14, 2020 9:31 AM - StreetInsider Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium September 14, 2020 9:30 AM - Globe NewsWire Regeneron (REGN) Reports RECOVERY COVID-19 Phase 3 Trial to Evaluate REGN-COV2 Investigational Antibody Cocktail in UK September 14, 2020 7:05 AM - StreetInsider RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK September 14, 2020 7:00 AM - PR NewsWire Regeneron (REGN) Reports Dupixent (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis September 14, 2020 6:12 AM - StreetInsider FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis September 14, 2020 1:00 AM - StreetInsider FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis September 14, 2020 12:59 AM - PR NewsWire Regeneron (REGN) SanoSNY) Reports New Results from Dupixent (dupilumab) Phase 3 Open-Label Extension Trial September 8, 2020 6:32 AM - StreetInsider Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma September 8, 2020 1:00 AM - StreetInsider Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma September 8, 2020 12:59 AM - PR NewsWire Form 4 REGENERON PHARMACEUTICAL For: Sep 01 Filed by: RYAN ARTHUR F September 3, 2020 4:18 PM - SEC Filing Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO September 3, 2020 7:00 AM - PR NewsWire Regeneron (REGN) Announces Late-breaking Libtayo Pivotal Data in Advanced NSCLC and Basal Cell Carcinoma to Be Presented at ESMO September 3, 2020 7:00 AM - StreetInsider Late-breaking Libtayo® (cemiplimab) Pivotal Data in Advanced Non-small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at ESMO September 3, 2020 6:59 AM - PR NewsWire REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm August 31, 2020 8:55 PM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Aug 27 Filed by: LAROSA JOSEPH J August 31, 2020 4:38 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 31 Filed by: SING GEORGE L August 31, 2020 4:37 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 28 Filed by: POON CHRISTINE A August 31, 2020 4:35 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 25 Filed by: Van Plew Daniel P August 27, 2020 4:36 PM - SEC Filing Regeneron Announces Investor Conference Presentations August 26, 2020 7:00 AM - PR NewsWire AstraZeneca starts trial of COVID-19 antibody treatment August 25, 2020 4:02 AM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Aug 20 Filed by: SING GEORGE L August 24, 2020 6:14 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 20 Filed by: SING GEORGE L August 24, 2020 6:14 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 21 Filed by: GOLDSTEIN JOSEPH L August 24, 2020 5:20 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 20 Filed by: Van Plew Daniel P August 24, 2020 4:48 PM - SEC Filing SHAREHOLDER ALERT: Lowey Dannenberg Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) for Potential Breaches of Fiduciary Duty by Its Board of Directors August 20, 2020 12:39 PM - StreetInsider Benchmark Downgrades Regeneron Pharma (REGN) to Hold August 20, 2020 6:50 AM - StreetInsider Regeneron (REGN) Announces NEJM Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol August 19, 2020 5:02 PM - StreetInsider New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol August 19, 2020 5:01 PM - PR NewsWire Roche, Regeneron link up to develop COVID-19 antibody cocktail August 19, 2020 7:39 AM - StreetInsider Regeneron (REGN) Announces Collaboration with Roche on Global Supply Development & Manufacturing of REGN-COV2 Investigational Antibody Combination for COVID-19 August 19, 2020 6:23 AM - StreetInsider Form 8-K REGENERON PHARMACEUTICAL For: Aug 18 August 19, 2020 6:02 AM - SEC Filing Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19 August 19, 2020 1:00 AM - PR NewsWire Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 August 19, 2020 1:00 AM - StreetInsider Big Tech drives S&P 500 to record high in coronavirus rally August 18, 2020 12:51 PM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Aug 11 Filed by: VAGELOS P ROY August 13, 2020 4:03 PM - SEC Filing Form 8-K REGENERON PHARMACEUTICAL For: Aug 07 August 12, 2020 4:32 PM - SEC Filing Regeneron (REGN) Announces FDA Accepts Evinacumab BLA for Priority Review as Treatment for Patients with HoFH August 12, 2020 7:01 AM - StreetInsider FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol August 12, 2020 7:00 AM - PR NewsWire Form 424B5 REGENERON PHARMACEUTICAL August 11, 2020 6:05 AM - SEC Filing Form FWP REGENERON PHARMACEUTICAL Filed by: REGENERON PHARMACEUTICALS, INC. August 7, 2020 4:49 PM - SEC Filing Regeneron Announces Pricing of Public Offering of Senior Unsecured Notes August 7, 2020 4:05 PM - PR NewsWire Form 424B3 REGENERON PHARMACEUTICAL August 7, 2020 9:28 AM - SEC Filing Regeneron Pharma (REGN) PT Raised to $725 at Credit Suisse After Earnings August 7, 2020 6:36 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $725 at Credit Suisse August 7, 2020 6:29 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $725 at Oppenheimer August 6, 2020 9:32 AM - StreetInsider Regeneron Pharma (REGN) PT Lowered to $611 at Morgan Stanley August 6, 2020 9:27 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $684 at Cowen August 6, 2020 8:13 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $675 at Barclays August 6, 2020 6:30 AM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Aug 03 Filed by: RYAN ARTHUR F August 5, 2020 5:10 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Aug 04 Filed by: Landry Robert E August 5, 2020 5:08 PM - SEC Filing Regeneron Pharma (REGN) PT Raised to $550 at JPMorgan, Following Earnings August 5, 2020 3:51 PM - StreetInsider U.S. to pay $1 billion for 100 million doses of Johnson & Johnson's COVID-19 vaccine candidate August 5, 2020 9:07 AM - StreetInsider Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30 August 5, 2020 7:37 AM - SEC Filing Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook August 5, 2020 7:21 AM - StreetInsider Form 8-K REGENERON PHARMACEUTICAL For: Aug 05 August 5, 2020 7:16 AM - SEC Filing Regeneron profit beats, expects early results from COVID-19 trials in September August 5, 2020 6:59 AM - StreetInsider Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat August 5, 2020 6:39 AM - StreetInsider Regeneron Reports Second Quarter 2020 Financial and Operating Results August 5, 2020 6:30 AM - PR NewsWire Regeneron (REGN) calls active into quarter results and outlook August 4, 2020 10:58 AM - StreetInsider Regeneron (REGN) weekly IV low into quarter release and Covid-19 development outlook August 4, 2020 6:47 AM - StreetInsider Eli Lilly tests antibody drug to halt COVID-19 spread in U.S. nursing homes August 3, 2020 9:20 AM - StreetInsider Next big COVID-19 treatment may be manufactured antibodies August 3, 2020 7:13 AM - StreetInsider Rival drugmakers launch joint trial of medicines for COVID-19 August 3, 2020 6:14 AM - StreetInsider Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas B July 29, 2020 10:25 PM - PR NewsWire Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas B July 29, 2020 9:00 PM - PR NewsWire Regeneron (REGN) Announces BARDA Procures its REGN-EB3 Investigational Ebola Treatment for National Preparedness July 29, 2020 7:22 AM - StreetInsider BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness July 29, 2020 7:00 AM - PR NewsWire Regeneron Pharma (REGN) PT Raised to $600 at Baird on Strong Eylea Data July 23, 2020 6:53 AM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Jul 20 Filed by: Fenimore Christopher R. July 22, 2020 4:32 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Jul 20 Filed by: Landry Robert E July 22, 2020 4:31 PM - SEC Filing Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications July 20, 2020 10:01 AM - StreetInsider Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications July 20, 2020 10:00 AM - Globe NewsWire Regeneron Pharma (REGN) PT Raised to $716 at Credit Suisse July 20, 2020 7:13 AM - StreetInsider Regeneron (REGN) call put ratio 3.5 calls to 1 put as shares rally 2% July 17, 2020 3:19 PM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Jul 13 Filed by: MURPHY ANDREW J July 15, 2020 4:56 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Jul 13 Filed by: MURPHY ANDREW J July 15, 2020 4:52 PM - SEC Filing Form CT ORDER REGENERON PHARMACEUTICAL July 15, 2020 9:43 AM - SEC Filing Regeneron Pharma (REGN) PT Raised to $619 at Morgan Stanley July 15, 2020 9:00 AM - StreetInsider Regeneron (REGN) IV into Moderna (MRNA) IV into disclosing COVID-19 vaccine data July 15, 2020 4:40 AM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Jul 14 Filed by: Landry Robert E July 14, 2020 4:18 PM - SEC Filing Regeneron (REGN) calls more active than puts as shares rally 3% July 14, 2020 2:26 PM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Jul 09 Filed by: Landry Robert E July 13, 2020 4:29 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Jul 07 Filed by: Landry Robert E July 9, 2020 4:30 PM - SEC Filing SunTrust Upgrades Regeneron Pharma (REGN) to Buy on Greater Confidence in Pipeline July 8, 2020 4:46 PM - StreetInsider Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020 July 8, 2020 4:30 PM - PR NewsWire Form 4 REGENERON PHARMACEUTICAL For: Jul 07 Filed by: Zoghbi Huda Y July 8, 2020 4:23 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Jul 07 Filed by: SING GEORGE L July 8, 2020 4:20 PM - SEC Filing Regeneron Pharma (REGN) PT Raised to $700 at Canaccord Genuity on $450M BARDA COVID-19 Grant July 8, 2020 7:49 AM - StreetInsider U.S. signs $450 million contract with Regeneron for COVID-19 therapy July 7, 2020 8:02 AM - StreetInsider Form 8-K REGENERON PHARMACEUTICAL For: Jul 06 July 7, 2020 7:29 AM - SEC Filing Regeneron (REGN) Secures $450M Contract from BARDA/DoD to Manufacture and Supply REGN-COV2 Anti-Viral Antibody Cocktail July 7, 2020 7:05 AM - StreetInsider Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail July 7, 2020 7:00 AM - PR NewsWire Regeneron (REGN) Starts Phase 3 COVID-19 Trial of REGN-COV2 July 6, 2020 7:03 AM - StreetInsider Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID) July 6, 2020 7:00 AM - PR NewsWire Regeneron (REGN), Sanofi (SNY) Announce Kevzara Phase 3 U.S. Trial in COVID-19 Patients Did Not Meet its Primary and Secondary Endpoints July 2, 2020 4:30 PM - StreetInsider Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients July 2, 2020 4:30 PM - StreetInsider Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients July 2, 2020 4:29 PM - PR NewsWire Form 4 REGENERON PHARMACEUTICAL For: Jul 01 Filed by: BROWN MICHAEL S July 2, 2020 4:03 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Jul 01 Filed by: RYAN ARTHUR F July 2, 2020 4:02 PM - SEC Filing Full Article List